Author Manuscript Published OnlineFirst on June 18, 2015; DOI: 10.1158/0008-5472.CAN-15-0248 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. An autoimmune response signature associated with the development of triple negative breast cancer reflects disease pathogenesis Hiroyuki Katayama1, Clayton Boldt1, Jon J Ladd2, Melissa M Johnson3, Timothy Chao2, Michela Capello1, Jinfeng Suo1, Jianning Mao3, JoAnn E Manson4, Ross Prentice2, Francisco Esteva5, Hong Wang1, Mary L Disis3, Samir Hanash1 1MD Anderson Cancer Center, 6767 Bertner Avenue, Houston Texas, 77030, USA 2Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, Washington, 98109, USA 3 Tumor Vaccine Group, University of Washington, 850 Republican Street, Box 358050, Seattle, Washington, 98109, USA 4 Division of Preventive Medicine, Brigham & Women's Hospital, Harvard Medical School, 900 Commonwealth Avenue 3rd Floor, Boston, MA 02215, USA 5 Division of Hematology/Oncology, Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY 10016, USA # Corresponding author: Samir Hanash, MD Anderson Cancer Center, 6767 Bertner Ave, Houston, TX, 77030, Phone: 713-745-5242, Fax: 713-792-1474, email:
[email protected] Running title: Autoantibody signatures in triple negative pre-diagnostic breast cancer Keywords: Breast cancer, Autoantibody, Pre-diagnostic, Triple negative, cytoskeletal proteins Conflicts of interest: Dr. Disis has an ownership interest with University of Washington over $10,000 and consultant positions with VentiRX, Roche, BMS, EMD, Serono and Immunovaccine. 1 Downloaded from cancerres.aacrjournals.org on September 30, 2021. © 2015 American Association for Cancer Research. Author Manuscript Published OnlineFirst on June 18, 2015; DOI: 10.1158/0008-5472.CAN-15-0248 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.